Compare moats
Up to three covered companies, band by band. Every call is a curated editorial judgment, never a disclosed figure — and every band carries its cited basis.
| AppLovin | SoundHound AI | Tempus AI | |
|---|---|---|---|
| Moat rating | narrow The filing's own words support a narrow moat. Auctions run 'at vast scale and at microsecond-level speeds,' revenue is earned only 'when our advertisers achieve their return on advertising spend targets,' and FY2025 adjusted EBITDA margin was 82.3%. What limits the width: clients 'are not required to enter into long-term agreements' and 'Substantially all of the Company's contracts with customers are cancelable at any time'; the solutions 'primarily operate in the mobile app ecosystem and specifically mobile gaming'; and distribution runs through 'the Apple App Store, the Google Play Store, and Meta' while AppLovin relies 'in part on IDFA.' | narrow The FY2025 10-K describes a real but limited edge: after an automotive design win a competing product may not be able to displace the winner because it is 'very unlikely that a customer will change complex technology until a product model is revamped', and it claims technical barriers to entry and cites over 359 granted and over 102 pending patents. The same filing concedes intense, price-sensitive competition from larger rivals that may be able to offer competing functionality 'at lower cost or free of charge' within larger offerings, possible pricing pressure from OEMs, master service agreements customers can terminate on six months to one year of prior written notice, and, to date, substantial net losses and negative cash flows from operating activities. The stickiness is real, but it has not yet produced profits. | narrow The FY2025 10-K documents a real asset: a network "connected in some way to more than 55% of all oncologists practicing in the United States" and "more than 65% of all academic medical centers," via "more than 700 unique data connections" across "more than 5,000 healthcare institution sites," with "broad data rights, including the rights to longitudinally updated data." Not eroding: revenue $693.4M to $1,271.8M (+83%), net loss narrowed from $705.8M to $245.0M. Not wide: still loss-making against "an accumulated deficit of $2.4 billion," with payment received on only "approximately 55% of our clinical oncology NGS tests and 50% of our hereditary tests." |
| Moat type | network effects Network effects, with a caveat. The 10-K states the loop: as more advertisers use the solutions 'we gain access to more data regarding users and user engagement,' 'further strengthening our scaled distribution,' and 'As our distribution grows, we gain better insights for Axon AI.' The mechanism is two-sided matching of advertiser demand to publisher supply, though much of the force comes from data-and-learning scale. It is not switching costs, since contracts are 'cancelable at any time,' nor intangibles or IP, since 'there can be no assurance that we will adequately protect our intellectual property or that it will provide any competitive advantage.' | switching costs The stickiest advantage in the 10-K is design-win lock-in: a product that did not win an OEM or Tier-1 design may not be able to displace the winner until the customer begins a new selection process, because the 10-K says customers are very unlikely to change complex technology until a product model is revamped. Private domains make SoundHound a long-term "partner" (the 10-K's quotation marks) because subscribing customers retain the ability to iterate and update their content on its platform. Patents are the weaker source: the filing warns that competitors 'may independently develop technologies that are substantially the same or superior' without infringing its rights. | network effects The filing states the mechanism: "Each product line is designed to enable and enhance the other, thereby creating network effects." That is the filing's own characterisation, so the rating rests on corroborating facts: 700+ data connections across 5,000+ sites with longitudinal rights; roughly 801,000 tests in FY2025 (about 340,500 Oncology) feeding the records Insights licenses; Insights working with "19 of the 20 largest public pharmaceutical companies based on 2024 revenue" at "approximately 126%" net revenue retention. Intangibles fit less well: the xT PMA, ADLT status, Paige's clearance and five CAP/CLIA labs are real, but named peers hold comparable approvals. |
| Leadership | at parity The filing discloses no share of any market, names 'Meta, Google, Amazon, and Unity Software' as competitors, and concedes rivals 'may have greater resources' and 'better technological or data analytics capabilities, or stronger brands or competitive positions in certain product segments.' Its one positional statement is parity language: 'We believe we compete favorably with respect to these factors.' Two unquantified points cut upward: Meta and Google are also clients, and MAX is called 'the preferred in-app bidding solution for many publishers worldwide.' | behind The 10-K calls SoundHound 'a global leader in conversational intelligence' with 'best-in-class speed and accuracy', but these are the company's own claims and it gives no share figure. Apart from the company's own positioning, such as its belief that some legacy vendors offer dated technologies, the 10-K's comparisons with rivals run against SoundHound: some current or potential competitors are large technology companies that have 'significantly greater financial, technical and marketing resources than SoundHound does', they may be able to respond more rapidly to new or emerging technologies, and its large competitors may have greater access to customer data, which the 10-K says provides them with a competitive advantage in developing new products and technologies. | at parity The filing claims no ranked lead; its positional language is hedged, as in "one of the largest sequencers of cancer patients... in the United States." Two disclosures cut the other way: the reimbursement goal is to become "more in line with other NGS providers who have adopted similar strategies, such as FMI and Guardant," and competitors "may have longer operating histories; larger customer bases; greater brand recognition and market penetration." Competition names Foundation Medicine (Roche), Caris, Guardant, Natera, Neogenomics, Quest, LabCorp, Flatiron, IQVIA, ConcertAI and major CROs, all unranked. Scaled positions on both sides support parity, not a top position. |
| Pricing power | strong Strong, with the mechanism shown. The 10-K states that 'Advertisers are charged dynamically based on their campaign goals , rather than a simple fixed price per impression or per action.' Growth composition is the evidence: FY2025 revenue +70% with 'the volume of installations increased 3% and net revenue per installation increased 72%'; H1 2026 +56% with per-installation revenue +75% against 'a decrease in the volume of installations of 10%.' Adjusted EBITDA margin was 82.3% in FY2025 and 84.2% in H1 2026, though payment is performance-contingent and contracts cancel at will. | weak The 10-K flags price sensitivity among customers, rival alternatives offered 'at significantly lower costs or free of charge', and the strong purchasing power of major OEMs, under which SoundHound may be expected to quote fixed prices or be forced to accept annual price-reduction commitments. GAAP gross margin, computed from the 10-K's revenue and cost of revenue, fell from 75.4% (FY2023) to 48.9% (FY2024) and 42.4% (FY2025). The company attributes both declines primarily to acquisitions: the FY2024 10-K cites Amelia and SYNQ3, including SYNQ3's lower-margin call-center agent business and amortization of acquired intangibles, and the FY2025 10-K cites Amelia and Interactions, including $14.1M and $0.8M of amortization of acquired intangibles. Neither passage attributes the decline to pricing. The Q2 2026 release (8-K filed 2026-08-05) reports GAAP gross margin up 6.1 points year over year to 45.1%, with non-GAAP gross margin flat at 58.4%. | weak Diagnostics prices are administered: after a CPT code is set, "CMS, establish payment levels and coverage rules under Medicare," delegating to MACs, while "Private payers establish their rates and coverage rules independently." Average revenue per Oncology test rose from about $1,510 to about $1,600, "driven primarily by increased Medicare reimbursement rates" — the payer moved the price. Collection came on "approximately 55% of our clinical oncology NGS tests and 50% of our hereditary tests," and payer "cost-saving initiatives... are likely to result in pricing pressures." The moderate pocket is confined to Data and applications ($316.4M of $1,271.8M). |
| Summary | One reportable segment: an AI-priced auction matching advertiser demand to publisher supply, where 'Revenue from Axon Ads Manager comprises substantially all of our revenue.' The filed flywheel is real - more advertiser spend yields more user-engagement data, 'further strengthening our scaled distribution,' which feeds Axon AI - and it converts: FY2025 revenue $5.48B, up 70%, at an 82.3% adjusted EBITDA margin, carried by price (net revenue per installation +72%) not volume (installations +3%). What the filing does not evidence is a lock. Contracts are cancelable at any time, revenue concentrates in mobile gaming, and the distribution and identifier layers belong to Apple, Google and Meta - two of whom are simultaneously named competitors and disclosed clients. Wide margins with no disclosed structural lock is narrow. | SoundHound sells independent, white-label voice and agentic AI to carmakers, TV/IoT makers, restaurants and enterprises. Its 10-K pitches this as the alternative to big-tech assistants that take over a brand's users and data. Its defensibility rests mainly on automotive design wins, which the 10-K says customers are very unlikely to change until a product model is revamped. It layered on the Amelia (Aug 2024) and Interactions (Sep 2025) acquisitions, and it completed the LivePerson acquisition on 2026-09-04 per that day's 8-K, whose press release cites a strengthened IP portfolio of over 750 patents. Against that, the 10-K lists rivals with far greater resources and data that may be able to offer competing functionality at lower cost or free, customers that may develop competing products, competitors that may build their own solutions on open-source software, and possible OEM pricing pressure. The 10-K reports substantial net losses and negative operating cash flows to date, and GAAP gross margin fell from 75.4% (FY2023) to 42.4% (FY2025), a decline the company attributes mainly to acquisition mix and amortization. The advantage looks narrow and not yet proven economically. | Tempus AI's durable asset is an installed provider network and the longitudinal data rights attached to it, not any single assay: connections to more than 55% of practicing U.S. oncologists and more than 65% of academic medical centers, 700+ data connections across 5,000+ institution sites. That network makes the linked clinical-molecular database sellable — Insights serves 19 of the 20 largest public pharmaceutical companies by 2024 revenue at roughly 126% net revenue retention, and the trial network (1,400+ trials signed, 40,000+ patients identified) depends on the sequencing base. Economics are improving: revenue up 83% to $1.27B, net loss down from $705.8M to $245.0M. It stops short of wide on the filing's own terms — a $2.4B accumulated deficit, payment on only ~55% of oncology and ~50% of hereditary tests, and Diagnostics prices set by CMS, MACs and private payers. |
| Chain position | Demand-side AI ad platform: it monetizes third-party mobile-game publishers' inventory and sells outcomes to advertisers, so it sits downstream of Apple/Google app distribution and Apple's IDFA identifier layer and upstream of publisher monetization. Meta and Google are simultaneously named competitors and disclosed clients. Single reportable segment after the June 2025 Apps divestiture. | Voice and agentic AI layer that OEMs, restaurants and enterprises embed under their own brand. Per the 10-K it combines its domains with third-party LLMs such as OpenAI's ChatGPT and runs on hosting facilities and third-party public clouds. | Tempus sits between clinical care and pharma R&D. It ingests data from 5,000+ institution sites, runs five CAP/CLIA labs (Chicago, Atlanta, Raleigh, Aliso Viejo, Minneapolis via OneOme), and sells Diagnostics to providers and payers ($955.4M FY2025, +111%, administered) and Data and applications to pharma ($316.4M, +31%, negotiated). The clinical output is the data business's input. |
| Products (share / barrier) |
|
|
|
| Long-horizon vote | +0.11 at weight 0.20 · swarm neutral Editorial prior, not backtested. | -0.15 at weight 0.20 · swarm neutral Editorial prior, not backtested. | -0.01 at weight 0.20 · swarm neutral Editorial prior, not backtested. |